167027-30-7

Basic information

• Product Name: METHYL 6-AMINO-1H-INDOLE-2-CARBOXYLATE
• Synonyms: METHYL 6-AMINO-1H-INDOLE-2-CARBOXYLATE;1H-Indole-2-carboxylicacid,6-amino-,methylester(9CI);6-Amino-1H-indole-2-carboxylic acid methyl ester
• CAS NO: 167027-30-7
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.2
• Product Categories: AMINOACID
• Mol File: 167027-30-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 415.407 °C at 760 mmHg
• Flash Point: 205.031 °C
• Appearance: /
• Density: 1.339 g/cm³
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 16.20±0.30(Predicted)
• CAS DataBase Reference: METHYL 6-AMINO-1H-INDOLE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-AMINO-1H-INDOLE-2-CARBOXYLATE(167027-30-7)
• EPA Substance Registry System: METHYL 6-AMINO-1H-INDOLE-2-CARBOXYLATE(167027-30-7)

Safety Data

• Hazardous Substances Data: 167027-30-7(Hazardous Substances Data)

Usage

General Description

Methyl 6-amino-1H-indole-2-carboxylate, a chemical compound with the molecular formula C11H11N2O2, is a derivative of indole-2-carboxylate. It is commonly used as a building block in organic synthesis and pharmaceutical research, particularly in the development of new drugs and pharmaceuticals. METHYL 6-AMINO-1H-INDOLE-2-CARBOXYLATE has a variety of potential applications in medicinal chemistry, including as a precursor for the synthesis of bioactive molecules and pharmaceutical intermediates. Methyl 6-amino-1H-indole-2-carboxylate has also been studied for its potential biological activities, showing promise for its antibacterial and antiviral properties. Overall, this chemical has significant potential for use in drug discovery and development due to its structural and functional properties.

Upstream product

• 428861-43-2 methyl 6-nitroindoline-2-carboxylate 
• 428861-42-1 6-nitroindoline-2-carboxylic acid 
• 16851-56-2 indolin-2-yl carboxylic acid 
• 1427164-16-6 6-acetamidoindole-2-carboxylic acid methyl ester 
• 122-85-0 para-acetamidobenzaldehyde 
• 1049677-82-8 1-(tert-butyl) 2-methyl 6-amino-1H-indole-1,2-dicarboxylate 
• 1093261-18-7 1-(1,1-dimethylethyl) 2-methyl 6-nitro-1H-indole-1,2-dicarboxylate 
• 10242-00-9 6-Nitro-1H-indole-2-carboxylic Acid 
• 136818-66-1 6-Nitro-1H-indole-2-carboxylic acid methyl ester 
• 541522-65-0 methyl 6-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1H-indole-2-carboxylate 

Downstream Products

• 1093255-84-5 6-amino-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-1H-indole-2-carboxamide trifluoroacetate 
• 1093261-27-8 6-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1H-indole-2-carboxylic acid 
• 541522-65-0 methyl 6-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1H-indole-2-carboxylate 

Relevant articles and documents

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives

Based on the chemical structure of Pyrroloquinoline quinone (PQQ), a novel class of indole-2-carboxylate derivatives was designed, synthesized and assayed for antiproliferative activity in cancer cells in vitro. The biological results showed that some der

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.